Diabetes Therapeutics Market By Product: Global Opportunity Analysis and Industry Forecast, 2020-2030

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market

CHAPTER 4: DIABETES THERAPEUTICS MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Injectables
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Oral antidiabetic Drugs
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country

CHAPTER 5: DIABETES THERAPEUTICS MARKET, BY REGION
5.1 Overview
5.1.1 Market size and forecast
5.2 North America
5.2.1 Key trends and opportunities
5.2.2 North America Market size and forecast, by Product
5.2.3 North America Market size and forecast, by country
5.2.3.1 U. S.
5.2.3.1.1 Market size and forecast, by Product
5.2.3.2 Canada
5.2.3.2.1 Market size and forecast, by Product
5.2.3.3 Mexico
5.2.3.3.1 Market size and forecast, by Product
5.3 Europe
5.3.1 Key trends and opportunities
5.3.2 Europe Market size and forecast, by Product
5.3.3 Europe Market size and forecast, by country
5.3.3.1 Germany
5.3.3.1.1 Market size and forecast, by Product
5.3.3.2 France
5.3.3.2.1 Market size and forecast, by Product
5.3.3.3 United Kingdom
5.3.3.3.1 Market size and forecast, by Product
5.3.3.4 Italy
5.3.3.4.1 Market size and forecast, by Product
5.3.3.5 Spain
5.3.3.5.1 Market size and forecast, by Product
5.3.3.6 Rest of Europe
5.3.3.6.1 Market size and forecast, by Product
5.4 Asia-Pacific
5.4.1 Key trends and opportunities
5.4.2 Asia-Pacific Market size and forecast, by Product
5.4.3 Asia-Pacific Market size and forecast, by country
5.4.3.1 China
5.4.3.1.1 Market size and forecast, by Product
5.4.3.2 Japan
5.4.3.2.1 Market size and forecast, by Product
5.4.3.3 India
5.4.3.3.1 Market size and forecast, by Product
5.4.3.4 Australia
5.4.3.4.1 Market size and forecast, by Product
5.4.3.5 Rest Of Asia Pacific
5.4.3.5.1 Market size and forecast, by Product
5.5 LAMEA
5.5.1 Key trends and opportunities
5.5.2 LAMEA Market size and forecast, by Product
5.5.3 LAMEA Market size and forecast, by country
5.5.3.1 Brazil
5.5.3.1.1 Market size and forecast, by Product
5.5.3.2 Saudi Arabia
5.5.3.2.1 Market size and forecast, by Product
5.5.3.3 South Africa
5.5.3.3.1 Market size and forecast, by Product
5.5.3.4 Rest of LAMEA
5.5.3.4.1 Market size and forecast, by Product

CHAPTER 6: COMPANY LANDSCAPE
6.1. Introduction
6.2. Top winning strategies
6.3. Product Mapping of Top 10 Players
6.4. Competitive Dashboard
6.5. Competitive Heatmap
6.6. Key developments

CHAPTER 7: COMPANY PROFILES
7.1 ASTRAZENECA PLC
7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Operating business segments
7.1.4 Product portfolio
7.1.5 Business performance
7.1.6 Key strategic moves and developments
7.2 BOEHRINGER INGELHEIM GMBH
7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Operating business segments
7.2.4 Product portfolio
7.2.5 Business performance
7.2.6 Key strategic moves and developments
7.3 ELI LILLY AND COMPANY
7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Operating business segments
7.3.4 Product portfolio
7.3.5 Business performance
7.3.6 Key strategic moves and developments
7.4 GLAXOSMITHKLINE PLC
7.4.1 Company overview
7.4.2 Company snapshot
7.4.3 Operating business segments
7.4.4 Product portfolio
7.4.5 Business performance
7.4.6 Key strategic moves and developments
7.5 NOVARTIS AG
7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Operating business segments
7.5.4 Product portfolio
7.5.5 Business performance
7.5.6 Key strategic moves and developments
7.6 NOVO NORDISK
7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Operating business segments
7.6.4 Product portfolio
7.6.5 Business performance
7.6.6 Key strategic moves and developments
7.7 SANOFI S. A.
7.7.1 Company overview
7.7.2 Company snapshot
7.7.3 Operating business segments
7.7.4 Product portfolio
7.7.5 Business performance
7.7.6 Key strategic moves and developments
7.8 TAKEDA PHARMACEUTICAL COMPANY LIMITED
7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Operating business segments
7.8.4 Product portfolio
7.8.5 Business performance
7.8.6 Key strategic moves and developments
7.9 johnson and johnson md&d
7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Operating business segments
7.9.4 Product portfolio
7.9.5 Business performance
7.9.6 Key strategic moves and developments
7.10 MERCK and CO., INC.
7.10.1 Company overview
7.10.2 Company snapshot
7.10.3 Operating business segments
7.10.4 Product portfolio
7.10.5 Business performance
7.10.6 Key strategic moves and developments

Executive Summary

According to this report, titled, 'Diabetes Therapeutics Market,' the diabetes therapeutics market size was valued at $118, 063.3 million in 2020, and is estimated to reach $317, 915 million by 2030, growing at a CAGR of 10.4% from 2021 to 2030.

Diabetes therapeutic is a drug used by diabetic patients to restore the blood glucose metabolism to a normal state. It includes insulin analogues and oral hypoglycemic agents.

The factors that drive the global diabetes therapeutics market growth include rise in geriatric population, increase in the prevalence of diabetes worldwide, sedentary lifestyle of people, development of affordable & effective diabetes therapeutics, growth in awareness among population about self-management of diabetes, and increase in support from the government. For instance, according to American Diabetes Association (ADA), in 2019, approximately 37.3 million Americans were diagnosed with diabetes. Moreover, surge in awareness of diabetes care and market potential in developing regions are expected to provide numerous opportunities for diabetes market share by company. However, side effects of diabetic drugs and stringent approval process for these drugs restrict diabetes therapeutics market trends.

Depending on product, the market is bifurcated into injectables and oral-antidiabetic drugs (OAD). The injectables segment is the highest contributor to the market growth owing to increase in prevalence of diabetes. The oral-antidiabetic drugs segment is anticipated to be lucrative for market players due to increase in prevalence of type 2 diabetes and rise in geriatric population.

North America was the leading revenue contributor to the global diabetes therapeutics market share in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to its well-developed healthcare industry, increase in geriatric population, and high prevalence rate of diabetes. However, Asia-Pacific is expected to grow at the highest CAGR of 11.2% during the forecast period, due to increase in the number of diabetes patients, high population base, and growth in disposable income in the region.

The top 10 diabetes drugs key players operating in the global diabetes therapeutics market include Astrazeneca Plc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Glaxosmithkline Plc., Johnson & Johnson, Merck & Co., Inc., Novartis Ag, Novo Nordisk, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

The COVID-19 outbreak is anticipated to have a negative impact on the growth of the diabetes therapeutics market. There was implementation of lockdown to control spread of COVID-19. Many hospitals were converted into COVID 19 centers due to which diabetics faced delays in treatment. For instance, according to the World Health Organization (WHO) report, as of December 19, 2021, over 273 million cases and over 5.3 million deaths have been reported globally. Furthermore, entire healthcare sector’s focus shifted toward COVID-19. Thus, COVID-19 adversely affected the growth of the diabetes therapeutics market.

Key Findings of Study

On the basis of products, the injectables segment was the highest contributor in 2020.

Region wise, North America garnered the largest revenue share in 2020, whereas Asia is anticipated to grow at the highest CAGR during the forecast period.

Companies Mentioned

• Astrazeneca PLC
• Boehringer Ingelheim GmbH
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Novartis AG
• Novo Nordisk
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Johnson and Johnson Md&D
• Merck and Co. Inc.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.